Werner Baumann, Bayer CEO (Malte Ossowski/SVEN SIMON/picture-alliance/dpa/AP Images)
Bayer drops an Ionis-partnered drug after sinking $240M into its development
Bayer is punting an Ionis Pharmaceuticals-partnered drug back to the biotech, giving up on a program on which it had spent more than $200 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
